12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Asunaprevir regulatory update

Bristol-Myers submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for an interferon- and ribavirin-free oral regimen of daclatasvir and asunaprevir to...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >